Download Image
    
Share
  
Post
Fenretinide for COVID-19
1 study with 351 patients
Hospital Icon Control
Hospital Icon Fenretinide Serious Outcome Risk
No significant improvements are seen in meta analysis to date.
COVID-19 Fenretinide studies. Dec 2025. c19early.org
0 0.5 1 1.5+ All studies -44% Mortality -44% RCTs -44% Late -44% Favorsfenretinide Favorscontrol
Fenretinide (LAU-7b) is an oral small molecule host-directed therapy that targets host cell membrane lipid pathways to exert antiviral and inflammation-resolving effects.
May 30
2024
 Houle et al., NCT04417257 RESOLUTION: A Double-blind, Randomized, Placebo-controlled, Phase II/III Study of the Efficacy and Safety of LAU-7b in the Treatment of Adult Hospitalized Patients With COVID-19 Disease
44% higher mortality (p=0.34). RCT 125 hospitalized COVID-19 patients showing no significant benefits with fenretinide (LAU-7b).